S

Sonnet BioTherapeutics Holdings
D

SONN

2.75000
USD
-0.24
(-8.03%)
Market Closed
Volume
4,818
EPS
-1
Div Yield
-
P/E
-3
Market Cap
2,303,562
OverviewSignalsIdeasNews
Related Instruments
    ABT
    ABT
    0.850
    (0.74%)
    118.14 USD
    D
    DGX
    3.615
    (2.30%)
    160.455 USD
    H
    HOLX
    1.040
    (1.34%)
    78.600 USD
    IDXX
    IDXX
    -2.54
    (-0.60%)
    421.30 USD
    P
    PACB
    -0.25500
    (-13.78%)
    1.59500 USD
    T
    TMDX
    -7.840
    (-8.87%)
    80.550 USD
    TMO
    TMO
    -19.95
    (-3.74%)
    514.06 USD
    V
    VEEV
    -16.200
    (-7.06%)
    213.260 USD
    More
News

Title: Sonnet BioTherapeutics Holdings Inc

Sector: Healthcare
Industry: Biotechnology
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.